Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab

Masanobu Nakata; Fumihiko Urabe; Yu Imai; Kosuke Iwatani; Yuzo Inaba; Juria Nakano; Kensuke Fujiwara; Masaki Hashimoto; Yuhei Koike; Yuya Iwamoto; Shuhei Hara; Keiichiro Miyajima; Wataru Fukuokaya; Mahito Atsuta; Kagenori Ito; Keiichiro Mori; Takafumi Yanagisawa; Masaya Murakami; Kojiro Tashiro; Shunsuke Tsuzuki; Masato Yamaguchi; Tatsuya Shimomura; Jun Miki; Takahiro Kimura

doi:10.1007/s10147-025-02937-5

Affiliated Institutions

Related Publications

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor , Johann S. de Bono , Kim N. +17 more

BACKGROUND: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic ca...

2021 New England Journal of Medicine 2181 citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono , Joaquı́n Mateo , Karim Fizazi +17 more

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

2020 New England Journal of Medicine 2067 citations

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith , Fred Saad , Simon Chowdhury +15 more

Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than w...

2018 New England Journal of Medicine 1271 citations

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Masanobu Nakata, 
                                
                                    Fumihiko Urabe, 
                                
                                    Yu Imai
                                
                                et al.
                            
                            (2025). 
                            Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab. 
                            International Journal of Clinical Oncology
                            
                            .
                            https://doi.org/10.1007/s10147-025-02937-5

Identifiers

DOI: 10.1007/s10147-025-02937-5